Sangani Hospitals Ltd

As of November 24, 2025, Sangani Hospital is considered undervalued and attractive compared to its peers, with a PE ratio of 33.75, despite a year-to-date return of -12.96%.

As of November 19, 2025, Sangani Hospital is considered undervalued with an attractive valuation grade, a PE ratio of 35.77, and potential for recovery despite a year-to-date stock return of -7.75%, especially when compared to more expensive peers like Max Healthcare and Narayana Hrudaya.

As of November 18, 2025, Sangani Hospital is fairly valued with a PE ratio of 37.31 and an EV to EBITDA of 36.62, showing strong short-term performance but facing challenges with a year-to-date return of -3.77% compared to its peers.

As of 18-Nov, Sangani Hospitals Ltd is seeing a price increase to 70.15, up 4.7%, and has outperformed its sector by 6.01%. The stock is trading above all key moving averages, indicating a positive trend, with a significant rise in delivery volume suggesting increased investor interest.

Sangani Hospital has shown steady growth in net sales and profitability over the past three years, with net sales increasing from 15.67 Cr in Mar'23 to 21.19 Cr in Mar'25. However, operating profit margins have decreased, and cash flow from operations has declined, indicating challenges in maintaining financial stability.

As of 11-Nov, Sangani Hospitals Ltd is seeing a price increase to 65.70, up 2.82%, and has outperformed its sector today. Despite recent short-term gains, the stock has struggled long-term, with a year-to-date decline of 9.88% and a year-over-year drop of 15.77%.

As of 29-Oct, Sangani Hospitals Ltd is facing a significant decline in stock price, currently at 61.25, down 8.58%. The stock has underperformed against the Sensex, with negative returns over one week and one month, indicating a bearish trend and cautious investor sentiment.

As of 17-Oct, Sangani Hospitals Ltd's stock price is declining at 65.75, down 2.52%, and has underperformed its sector and the Sensex. Despite a 25% increase in delivery volume, the stock has seen significant losses over the past week and month, reflecting ongoing challenges in attracting investor confidence.

As of October 16, 2025, Sangani Hospital is considered undervalued with an attractive valuation grade, featuring a PE ratio of 35.88, an EV to EBITDA of 30.42, and a ROCE of 10.33%, making it a compelling investment opportunity compared to its peers like Apollo Hospitals and Max Healthcare.

As of 26-Sep, Sangani Hospitals Ltd's stock price is declining at 70.05, down 4.95%, with significant drops in delivery volume and underperformance against its sector. Despite a strong year-over-year performance of 65.02%, recent trends indicate falling investor participation and a weaker short-term return compared to the benchmark.

As of 23-Sep, Sangani Hospitals Ltd is trading at 77.00, reflecting a 3.36% increase and strong performance compared to its sector and the broader market. However, a 37.5% drop in delivery volume raises concerns about the sustainability of this upward trend.

As of September 5, 2025, Sangani Hospital's valuation has shifted to fair with a PE ratio of 38.03, despite a strong 63.62% return over the past year, outperforming the Sensex's decline, while its peers Apollo Hospitals and Narayana Hrudaya are rated attractive and expensive, respectively.

As of September 5, 2025, Sangani Hospital's valuation has shifted from attractive to fair, with a PE ratio of 38.03 and strong stock performance of 63.62% over the past year, indicating potential for growth despite its current fair valuation compared to peers.

As of September 5, 2025, Sangani Hospital is fairly valued with a PE ratio of 38.03 and has outperformed the Sensex with a 1-year return of 63.62%, while its peers have higher valuations.

As of September 3, 2025, Sangani Hospital is considered undervalued with an attractive valuation grade, a PE ratio of 36.14, a PEG ratio of 0.00, and a strong performance of 62.72% return over the past year, outperforming the Sensex despite a year-to-date decline of 4.8%.

As of September 1, 2025, Sangani Hospital is fairly valued with a PE ratio of 37.24 and strong stock performance, achieving a 66.67% return over the past year, despite a shift in its valuation grade from attractive to fair.

As of August 29, 2025, Sangani Hospital is considered undervalued with an attractive valuation grade, a PE ratio of 35.59, and strong performance, having returned 59.29% over the past year, outperforming the Sensex despite a recent stock price decline.

As of August 29, 2025, Sangani Hospital is considered undervalued with an attractive valuation grade, a PE ratio of 35.59, and a strong 59.29% return over the past year, significantly outperforming the Sensex, while its peers like Max Healthcare and Apollo Hospitals are classified as expensive.

As of August 29, 2025, Sangani Hospital is considered undervalued with an attractive valuation grade, a PE ratio of 35.59, and a strong performance of 59.29% return over the past year, significantly outperforming the Sensex.